BWH SCC Staging: Alternative system focused on high-risk tumor features.
High-Risk Tumor Features
Awaiting Findings
Select the high-risk features found in the pathology report to determine the BWH stage and nodal risk.
Guidelines & Evidence
Verified
Last Review: 2026-07-17
When to Use
When to Use
The Brigham and Women's Hospital (BWH) staging system is used to risk-stratify primary cutaneous squamous cell carcinoma (cSCC) for nodal metastasis and disease-specific death. It was developed as a clinically superior alternative to the AJCC 7th edition (and validated against the 8th edition), specifically addressing the failure of AJCC T2 to discriminate between low- and high-risk tumors. It is particularly valuable for identifying the small subset of cSCC (BWH T2b/T3) that carries disproportionate metastatic risk.
Indications
All primary invasive cutaneous SCC following pathological diagnosis
Risk stratification before determining need for nodal staging (ultrasound, SLNB)
Determining eligibility for adjuvant radiation therapy discussion
Multidisciplinary tumor board stratification for high-risk cSCC
Prognostic counseling in immunocompromised patients (transplant, CLL, HIV)
When NOT to Use
SCC of the lip or ear — these sites have distinct prognostic data and some guidelines use AJCC head/neck staging
SCC in situ (Bowen's disease) — not invasive; not applicable
Mucosal SCC (oral, anogenital, conjunctival) — separate staging systems apply
Merkel cell carcinoma — completely separate staging
How it Works
The Four Risk Factors
1. Tumor diameter ≥ 2 cm
2. Poorly differentiated histology (moderately differentiated does NOT qualify)
3. Perineural invasion involving a named nerve OR nerve caliber ≥ 0.1 mm
4. Tumor invasion beyond subcutaneous fat (e.g., into muscle, cartilage, or bone)
Staging Categories & Nodal Metastasis Risk
| T1 | 0 risk factors — nodal metastasis risk ≈ 0.1% |
| T2a | 1 risk factor — nodal metastasis risk ≈ 3% |
| T2b | 2–3 risk factors — nodal metastasis risk ≈ 21% |
| T3 | 4 risk factors OR bone invasion — nodal metastasis risk ≈ 67% |
Pathophysiological Basis
cSCC arises from keratinocytes chronically damaged by UV radiation (predominantly UVA/UVB), accumulating mutations in TP53, CDKN2A, and RAS pathway genes. Immunosuppression (organ transplant recipients, CLL, HIV) amplifies risk 65–250-fold by impairing T-cell surveillance. Poor differentiation signals higher proliferative rate, reduced gap-junction communication, and increased invasion potential. Perineural invasion enables neural lymphatic spread to regional nodes even in clinically node-negative disease. Tumors invading beyond subcutaneous fat have crossed the structural barrier that normally confines local spread.
Clinical Pearls
Clinical Pearls
The BWH T1 vs. T2a vs. T2b distinction is the primary utility in clinical practice — it separates tumors with near-zero nodal risk from those with 3% and 21% risk, respectively.
AJCC 8th edition cSCC staging (for head/neck) has poor prognostic discrimination for the key high-risk subset. Multiple validation studies confirm BWH outperforms AJCC in separating metastatic from non-metastatic cSCC.
Immunosuppressed patients (solid organ transplant) develop more aggressive cSCC — BWH stage still applies, but the nodal risk at each stage is compounded. These patients may be offered SLNB or adjuvant RT at lower BWH thresholds than in immunocompetent patients.
Poorly differentiated histology must be confirmed by dermatopathology on the excision specimen, not just the diagnostic shave biopsy, as sampling can be unrepresentative.
Perineural invasion (PNI): incidental PNI of small unnamed nerves (< 0.1 mm) does NOT meet the BWH criterion for a risk factor; must be named nerve OR caliber ≥ 0.1 mm.
BWH vs. AJCC 8th Edition
The AJCC 8th edition cSCC staging is designed for head and neck SCC in the context of nodal/distant staging and radiation planning. The BWH system is a pure primary tumor staging system optimized for predicting nodal metastasis risk across all body sites. Many dermatology practices use BWH as their primary prognostic tool and AJCC for communication with oncology/ENT teams.
Limitations
BWH was derived and validated primarily in immunocompetent patient cohorts — transplant recipients and other immunosuppressed groups may have higher metastatic risk at each stage.
The system does not incorporate anatomical site (lip, ear, scalp — known high-risk sites) as a factor.
PNI definition (≥ 0.1 mm caliber) requires careful quantitative reporting from dermatopathology — not all pathology reports quantify nerve caliber.
Next Steps
BWH T1 (0 risk factors, < 0.1% nodal metastasis risk)
01
Standard wide local excision with clear margins (typically 4–6 mm clinical margin for well-differentiated SCC < 2 cm on non-facial sites; larger for facial sites).
02
No imaging or nodal staging required in immunocompetent patients.
03
Annual full-skin examination and regional lymph node palpation.
04
Patient education: sun protection, self-examination, and re-presentation if any new nodules or symptoms.
BWH T2a (1 risk factor, ~3% nodal metastasis risk)
01
Excision with adequate surgical margins — Mohs micrographic surgery for anatomically complex sites (face, scalp, ears).
02
Clinical regional lymph node examination; ultrasound for any palpable or clinically suspicious lymph nodes.
03
Consider adjuvant radiation therapy discussion — particularly for perineural invasion involving large-caliber named nerves.
04
Dermatology surveillance every 3–6 months × 2 years, then every 6–12 months.
BWH T2b (2–3 risk factors, ~21% nodal metastasis risk)
01
Excision with clear margins — Mohs preferred for high-risk anatomical sites.
02
Mandatory nodal staging: regional lymph node ultrasound and consider SLNB.
03
Multidisciplinary tumor board review — dermatology, surgical oncology, radiation oncology.
04
Adjuvant radiation therapy to primary site and/or regional nodes is frequently offered.
05
Imaging: consider CT neck/parotid region for head/neck primaries; PET-CT for suspected nodal disease.
06
Dermoscopy and full-skin surveillance every 3 months × 2 years.
BWH T3 (4 factors or bone invasion, ~67% nodal metastasis risk)
01
Radical surgical excision — often requiring craniofacial or reconstructive surgical input.
02
Mandatory nodal staging and imaging (CT ± PET-CT).
03
Adjuvant radiation therapy is standard of care.
04
Consider systemic therapy: cemiplimab (PD-1 inhibitor, FDA-approved for locally advanced or metastatic cSCC) for unresectable or metastatic disease.
05
Enroll in clinical trial where available.
06
Multidisciplinary tumor board review is mandatory.
The Evidence
BWH Staging — Derivation Study
Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system.
Jambusaria-Pahlajani A et al. • JAMA Dermatol.. 2013;149(4):402-10. Derivation cohort from BWH. Proposed 4-factor BWH staging (T1–T3) demonstrating superior nodal metastasis risk stratification vs. AJCC 7th edition. Nodal metastasis rates: T1 0.1%, T2a 3%, T2b 21%, T3 67%.
View SourceExternal Links
Origins & History
The Brigham and Women's Hospital (BWH) staging system for cutaneous squamous cell carcinoma was developed by Dr. Arash Jambusaria-Pahlajani and colleagues at Brigham and Women's Hospital, Harvard Medical School, Boston, in collaboration with Dr. Pritvi Kanetsky and Dr. Pritesh Karia. Published in JAMA Dermatology in 2013, it arose from the recognized clinical inadequacy of the AJCC 7th edition T2 category, which grouped tumors with widely divergent metastatic risk (from 3% to 67%) into a single stage. The BWH system uses four objectively measurable pathological risk factors to create four distinct stages with monotonically increasing nodal metastasis rates. It has been validated in multiple independent cohorts across North America, Europe, and Australia, and is widely endorsed by dermatology and head/neck oncology guidelines.
Last Comprehensive Review: 2026-07-17